RT Journal Article
SR Electronic
T1 Application of Risk Assessments in the Design of the Overall Viral Control Strategy Used during the Manufacture and Testing of Live Virus Vaccines
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 730
OP 736
DO 10.5731/pdajpst.2011.00851
VO 65
IS 6
A1 Sridhar Pennathur
YR 2011
UL http://journal.pda.org/content/65/6/730.abstract
AB CONFERENCE PROCEEDING Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in Bethesda, MD, USA; December 1–3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda, MD) and Michael Wiebe (San Francisco, CA) It is important to include a risk assessment process in the overall viral control strategy used during the manufacture and testing of live virus vaccines. Because the product is itself a virus, traditional viral clearance steps are generally not included in the manufacturing process, and there is normally no inactivation step in the manufacturing process either. The risk assessment is therefore necessary to identify potential sources for entry of adventitious agents into the vaccine, and to develop a strategy to minimize or eliminate the sources through which adventitious agents can enter the vaccine. The risk assessment can also be used to tailor the biosafety testing that is performed on raw materials, vaccine seeds, vaccine bulk materials, and final product. Biosafety testing is normally designed to ensure the detection of both known and unknown adventitious agents, but the results of the risk assessment can be used to put in place a biosafety testing strategy designed to maximize the detection of an adventitious agent that is potentially likely to be present in the vaccine. The risk assessment therefore enables the development of a comprehensive viral control strategy and provides a higher level of assurance that the vaccine will be free from contamination by adventitious agents.